Fig. 3From: Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalizationViability of SCC61 and A431 cells treated with test compounds. a SCC61 or b A431 cells were treated for 72 h with vehicle (black bars) or indicated agents. Erlotinib (grey bars) was used at 2 μM, and cetuximab (white bars) at 4 μM, while test compounds were used at 10 μM. *, P <0.05 in reference to vehicle treated cellsBack to article page